Celldex is currently studying several therapeu
Post# of 22755
Posted On: 03/31/2016 1:51:19 PM
Celldex is currently studying several therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines in clinical trials. In many cases, these clinical trials are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. We are currently conducting clinical trials in the following indications:
Bladder Cancer
Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Hematologic Cancers
Melanoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Bladder Cancer
Open to Enrollment
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →
Breast Cancer
Open to Enrollment
Study of Glembatumumab Vedotin in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC). Registrational Phase 2. NCT01997333. Link to ClinicalTrials.gov →
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →
Colorectal Cancer
Open to Enrollment
A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →
Fully Enrolled
A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →
Head and Neck Cancer
Open to Enrollment
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →
A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →
Hematologic Cancers
Open to Enrollment
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs. Phase 2. NCT02200380. Link to ClinicalTrials.gov →
Fully Enrolled
A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →
Melanoma
Open to Enrollment
A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma. Phase 2. NCT02302339. Link to ClinicalTrials.gov →
A Study of Varlilumab and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma. Phase 1/2. NCT02413827. Link to ClinicalTrials.gov →
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →
A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →
Fully Enrolled
A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →
Non-Small Cell Lung Cancer
Open to Enrollment
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →
A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →
Fully Enrolled
A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →
Ovarian Cancer
Open to Enrollment
A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →
Fully Enrolled
A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →
Prostate Cancer
Fully Enrolled
A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →
Renal Cell Carcinoma
Open to Enrollment
A Study of Varlilumab and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Phase 1/2. NCT02386111. Link to ClinicalTrials.gov →
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →
Fully Enrolled
A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTria
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼